Global Bipolar Disorder Market

Global Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants), By Type(Bipolar I Disorder, Bipolar II Disorder) - Industry Forecast 2024-2031


Report ID: SQMIG35I2095 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 67 | Figures: 75

Global Bipolar Disorder Market Dynamics

Bipolar Disorder Market Drivers

Emphasis on improving product portfolio and the growing number of mental illnesses is expected to propel the market growth

  • The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.
  • Bipolar disorder prevalence is rising, there are more government efforts to raise public awareness of its consequences, there is a strong demand for antidepressants, and there is a desire to lessen the illness burden of bipolar disorder. 

Bipolar Disorder Market Restraints

Lack of medications and the correct line of treatment to create market challenges

  • The patent expirations of several key products, including Latuda (lurasidone) from Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals, Abilify Maintena (aripiprazole ER) from Otsuka Pharmaceutical and Lundbeck, and Risperdal Consta (risperidone PR) from Johnson and Johnson, are expected to further increase the constraints in the bipolar disorder market during the forecast period. Lithium is one example of a generic drug with high usage that is anticipated to last the entire projected period.
  • Lack of appropriate diagnostic methods for the diagnosis of the disease and the negative side effects of treatments for bipolar disorder are anticipated to restrain market expansion. On the other hand, developments in drug combination therapy offer profitable prospects for market expansion in the near future.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Bipolar Disorder Market size was valued at USD 5.25 billion in 2019 and is poised to grow from USD 5.36 billion in 2023 to USD 6.4 billion by 2031, growing at a CAGR of 2.00% in the forecast period (2024-2031).

Global bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Allergan (Ireland)', 'AstraZeneca plc', 'Bristol Myers Squibb Company', 'Eli Lilly and Company', 'GlaxoSmithKline plc', 'H. Lundbeck A/S', 'Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson)', 'Otsuka Holdings Co. Ltd.', 'Pfizer Inc.', 'Sunovion Pharmaceuticals Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Takeda Pharmaceutical Company Limited', 'Abbott Laboratories', 'Novartis International AG', 'Alkermes plc', 'AbbVie Inc.', 'Merck & Co. Inc.', 'Mylan N.V.', 'Neurocrine Biosciences Inc.', 'Vanda Pharmaceuticals Inc.'

The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.

Rising cases of mental illness: As non-ambiguous cases of illness have been increasingly prevalent in the population, bipolar disorder in children and adolescents has become a common diagnosis.

Geographically, North America is anticipated to dominate the global bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the global market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Bipolar Disorder Market

Product ID: SQMIG35I2095

$5,300
BUY NOW GET FREE SAMPLE